BS (Henan Normal U); MPhil (Institute of Genetics, Chinese Academy of Sciences); PhD (Baylor College of Medicine)
S Y and H Y Cheng Professor in Stem Cell Biology and Regenerative Medicine
Rm 5-06, 5/F, Jockey Club Building for Interdisciplinary Research,
5 Sassoon Road, Hong Kong
T +852 2831 5407
pliu88@hku.hk
Professor Pengtao Liu is the S Y and H Y Cheng Professor in Stem Cell Biology and Regenerative Medicine at the School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong. He is the founding and managing director of the InnoHK Centre for Translational Stem Cell Biology at Hong Kong Science and Technology Park. Professor Liu earned his PhD from Baylor College of Medicine and completed postdoctoral training at the National Cancer Institute in the United States.
Prior to joining HKU, he established and led a research laboratory at the Wellcome Trust Sanger Institute, Cambridge, and served as an affiliate faculty member at the Cambridge University Stem Cell Institute. His key contributions include participating in large-scale mouse genetics projects, discovering a novel killer cell that eliminates cancer cells, and developing Expanded Potential Stem Cells (EPSCs). Notably, he established the first stable pluripotent stem cells from pig preimplantation embryos.
In Hong Kong, Professor Liu spearheads major research initiatives at HKU and InnoHK CTSCB, supported by the InnoHK initiative of the Innovation and Technology Commission of the Hong Kong Special Administrative Region Government. As a pioneer in stem cell research, his team continues to advance scientific frontiers through innovative discoveries with the potential to revolutionize medicine. Their work helps position Hong Kong as a global hub for stem cell research and cell-based therapies, shaping the future of regenerative medicine and personalised treatments.
The Liu lab developed the Expanded Potential Stem Cell (EPSC) technology, which has wide-ranging applications in fundamental biology, regenerative medicine, cell-based therapy, organ transplantation, biotechnology and agriculture. The lab's primary objective is to generate and characterize novel stem cell lines exhibiting totipotency features across multiple mammalian species, and to direct these stem cells to generate functional cell types, such as immune cells, both in vitro and in vivo. This approach is fundamental for advancing our understanding of human development, improving therapeutic strategies, and expanding the therapeutic potential of stem cells. The lab employs advanced molecular and functional methodologies, particularly single-cell multi-omics, to elucidate the underlying molecular mechanisms governing stem cell biology.
Investigation of developmental potency association with chromatin structure in preimplantation embryos and expanded potential stem cells by single cell multi-omics
2022
Preclinical study of TRAC-CFR64-ITNK cells derived from totipotent stem cells in the treatment of malignant tumours
2025
Clinical Translational Study on The Treatment of Malignant Tumors with Novel Tumor Killer Cell CAR-ITNK
2022
Establishment of Centre for Translational Stem Cell Biology
2020
Molecular and functional dissection of totipotency acquisition in pluripotent stem cells and somatic cells
2025
Investigation of Human Trophoblast Stem cell differentiation as a novel cellular model for anti-aging study
2024
Investigation of Tumor suppressor protein p53 in cell lineage development in mouse pre-implantation embryos and in human pluripotent stem cell differentiation
2023
Functional and Single Cell Genomics Investigation of METTL3 and m6A RNA Methylation in Human Cell Lineage Development
2022
Single Cell Genomics and Functional Investigation of BMP Signalling in Expanded Potential Stem Cells
2021
Genome Edited Porcine Expanded Potential Stem Cells for Xenotransplantat
2020
Last Update : 2025-12-10